BioAffinity.jpg
bioAffinity Technologies Opens Test Validation Trial of CyPath® Lung
17 juil. 2018 14h40 HE | bioAffinity Technologies, Inc.
SAN ANTONIO, July 17, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has commenced its test validation trial for CyPath® Lung, an...